Corcept falls as appeals court sides with Teva in Korlym...

2026-02-19 11:10:48 ET More on Corcept Therapeutics Why Corcept Therapeutics' Relacorilant Fell Short And What It Means For The Company Corcept: Korlym Defies Generics As Relacorilant Hits An FDA CRL (Rating Upgrade) Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug Corcept down as FDA revises rejection letter for hormonal disorder therapy Corcept climbs as ovarian cancer therapy succeeds in late-stage trial Read the full article on Seeking Alpha For further details see: Corcept falls as appeals court sides with Teva in Korlym patent dispute